The object of the invention is to develop an agent by means of which mesenchyme-epithelial cell interaction can be influenced in vivo.

Accordingly, the invention includes a method of regenerating a mesenchymally-derived tissue by contacting the tissue with a composition containing an isolated adult mesenchymal stem cell, which are apoptosis-resistant.

Usually, the methods involve direct implantation of mesenchyme into suitably prepared sites of adult animals.

The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).

The modality of treatment may include leukapheresis of white blood cells or infusion of mesenchymal stem cells.

Human mesenchymal stem cells having the phenotype SH3+, CD45+ can be isolated.

The invention is related to inhibition of Smad3 to ameliorate Smad3 mediated epithelial to mesenchymal transition.

It is derived from dental mesenchyme (papilla) or follicle.

The mesenchyme in the arches give rise to muscles.

These precursor mesenchymal item cells are useful for treatment of patients in need of mesenchymal stem cells.

It induces development of the mesenchyme into the primordia of bones.

They can grow in all organs, arising from mesenchyme tissue.

The mandible is also formed by membranous ossification of mesenchymal tissue surrounding Meckel's cartilage.

The growth factor derived from PDGF platelets will then stimulate the growth of the mesenchyme.

The present invention relates to the use of AxI as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject.